Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Rejoins ABPI After Long Absence To Help Forum Address Brexit

Executive Summary

Roche's decision to return to the UK industry body the ABPI reflects the Swiss company’s considerable commercial interests in Britain and the need for drug makers operating there to work more closely together as the Brexit process begins.

You may also be interested in...



New UK Cancer Drugs Fund Dismays Pharma, Charities

The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation. Pharma companies believe they will have to shoulder additional financial risks while patients will still not get full access to the medicines they need.

Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset

The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.

Roche and the ABPI: What Does it Mean for Self-Regulation?

Roche's decision not to rejoin the UK industry body the ABPI after its six-month suspension for breaching the advertising code of practice has understandably made waves in the sector. After all, Roche is a pillar of the pharmaceutical establishment and its departure will affect both the ABPI's image and its revenues. But are there any implications for the future of self-regulation by the industry, as some have suggested?

Topics

UsernamePublicRestriction

Register

SC097217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel